Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data

Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine the value for money to the English National Health Service (NHS) of adding AAP to SOC....

Descripción completa

Detalles Bibliográficos
Autores principales: Clarke, Caroline S., Hunter, Rachael M., Gabrio, Andrea, Brawley, Christopher D., Ingleby, Fiona C., Dearnaley, David P., Matheson, David, Attard, Gerhardt, Rush, Hannah L., Jones, Rob J., Cross, William, Parker, Chris, Russell, J. Martin, Millman, Robin, Gillessen, Silke, Malik, Zafar, Lester, Jason F., Wylie, James, Clarke, Noel W., Parmar, Mahesh K. B., Sydes, Matthew R., James, Nicholas D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162346/
https://www.ncbi.nlm.nih.gov/pubmed/35653395
http://dx.doi.org/10.1371/journal.pone.0269192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162346/
https://www.ncbi.nlm.nih.gov/pubmed/35653395
http://dx.doi.org/10.1371/journal.pone.0269192

Ejemplares similares